| 2024 | | A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study) | 김혜진 |
| 2017 | | Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data | 김대중, 하경화 |
| 2021 | | Cardiovascular safety of sodium glucose cotransporter 2 inhibitors as add-on to metformin monotherapy in patients with type 2 diabetes mellitus | 김대중, 전자영, 하경화 |
| 2022 | | Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study | 김혜진 |
| 2011 | | Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naive Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study | 이관우 |
| 2011 | | Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. | 강엽, 김대중, 김혜진, 이관우, 한승진 |
| 2022 | | Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat | 이성준, 이진수, 조은혜, 홍지만 |
| 2023 | | Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study | 이관우 |
| 2007 | | Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. | 김대중, 이관우 |
| 2024 | | Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study | 한승진 |
| 2023 | | Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension | 김혜진 |
| 2017 | | Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) | 이관우 |
| 2018 | | Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial | 이관우 |
| 2024 | | Efficacy and Safety of Metformin and AtorvastatinCombination Therapy vs. Monotherapy with EitherDrug in Type 2 Diabetes Mellitus and DyslipidemiaPatients (ATOMIC): Double-Blinded RandomizedControlled Trial | 김대중 |
| 2023 | | Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study) | 김세혁 |
| 2019 | | Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial | 이관우 |
| 2018 | | Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program | 김대중, 김혜진, 이관우, 전자영, 한승진 |
| 2011 | | Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. | 김혜진 |
| 2019 | | Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study | 이관우 |
| 2017 | | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies | 김대중, 이광재 |
| 2015 | | Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. | 이관우 |
| 2018 | | Long-term effects on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial | 이관우 |
| 2016 | | Metformin induced acute pancreatitis and lactic acidosis in a patient on hemodialysis. | 김흥수, 박인휘, 신규태, 이연경, 임기현 |
| 2018 | | Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort | 김대중, 김혜진, 이관우, 전기홍, 전자영, 한승진 |
| 2014 | | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). | 정용식 |
| 2019 | | PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin | 변혜은, 이다근 |
| 2019 | | Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study | 김대중, 하경화 |
| 2014 | | Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells | 임인경, 최용원 |
| 2007 | | The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. | 김대중 |
| 2014 | | The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. | 김대중, 김혜진, 이관우, 한승진 |
